BioMed Central Infectious Diseases
Aminoglycosides are a critical component of multidrug-resistant tuberculosis (MDR-TB) treatment but data on their efficacy and adverse effects in Botswana is scarce. We determined the effect of amikacin on treatment outcomes and development of hearing loss in MDR-TB patients. Patients started on MDR-TB treatment between 2006 and 2012 were included. Multivariate analysis was used to determine the effect of amikacin on treatment outcomes and development of hearing loss.
Modongo, Chawangwa; Sobota, Rafal S.; Kesenogile, Boikobo; and Ncube, Ronald, "Successful MDR-TB Treatment Regimens Including Amikacin are Associated with High Rates of Hearing Loss" (2014). Open Dartmouth: Faculty Open Access Articles. 627.